Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Ballentine Partners LLC

Ballentine Partners LLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,831 shares of the company’s stock after selling 1,497 shares during the quarter. Ballentine Partners LLC’s holdings in Takeda Pharmaceutical were worth $234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in TAK. Rise Advisors LLC acquired a new position in Takeda Pharmaceutical in the first quarter worth $26,000. GAMMA Investing LLC acquired a new position in Takeda Pharmaceutical in the fourth quarter worth $28,000. Principal Securities Inc. acquired a new position in Takeda Pharmaceutical in the fourth quarter worth $28,000. First United Bank & Trust acquired a new position in Takeda Pharmaceutical in the fourth quarter worth $29,000. Finally, Lindbrook Capital LLC boosted its holdings in Takeda Pharmaceutical by 40.6% in the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock worth $58,000 after purchasing an additional 1,174 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $12.92 on Thursday. The company has a market cap of $40.87 billion, a PE ratio of 23.48, a P/E/G ratio of 0.36 and a beta of 0.55. The company has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $13.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.11 and a quick ratio of 0.58. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $16.39.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.